Building a realistic model of the human brain is a crucial part of understanding brain development, as well as neurological disorders such as Alzheimer's or Parkinson's disease. Using human stem cells, researchers have created a 3-D model of the human brain - and new research investigates how similar it is to a real brain.

Male hypogonadism is a condition affecting almost a third of the elderly male population. The most common treatment option is testosterone replacement therapy, but the practice can have significant side effects. A new development in stem cell research suggests an alternative treatment for hypogonadism may soon become available.

Single intracerebral doses of CTX-DP up to 20 million cells induced no adverse events and were associated with improved neurological function. Our observations support further investigation of CTX-DP in stroke patients.

German pharmaceuticals giant Bayer AG and U.S. health care investor Versant Ventures plan to establish a stem-cell research company, marking the latest effort by a big pharmaceutical company to develop new and innovative drugs by joining with venture capital and biotechnology firms.

em cells can develop into many different types of cells, such as muscle cells, red blood cells, or neurons. Given their special regenerative ability, stem cells can be used to treat a wide range of diseases. A team of researchers uncovers new details involved in the process of turning stem cells into motor neurons.

Pausing embryonic stem cells can be induced directly in cultured ES cells and sustained for weeks without appreciable cell death or deviations from cell cycle distributions.

The device consists of sensors encased in a flexible silicone shell and flanked on either side by electrodes. It sticks to the skin like a plaster or temporary tattoo and measures just 20 millimetres across.

A modified virus can repair diseased livers by turning bad cells into good. The treatment could one day offer a lifeline to thousands of people with liver failure.

A French team claiming the achievement has moved a stage closer to convincing sceptics by having the work published in a peer-reviewed journal. But some researchers say the evidence offered still falls short of what?s required to make such a large and historic claim.

In a paper published today in Science Translational Medicine, researchers from Fred Hutchinson Cancer Research Center shared data from an early-phase study of patients with advanced non-Hodgkin lymphoma (NHL) who received JCAR014, a Chimeric Antigen Receptor (CAR) T cell treatment, and chemotherapy. CAR T cells are made from a patient?s own immune cells that are then genetically engineered to better identify and kill cancer cells.